Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Monopar Therapeutics Inc (MNPR)

Monopar Therapeutics Inc (MNPR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 43,540
  • Shares Outstanding, K 12,920
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,100 K
  • 60-Month Beta 1.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.21
Trade MNPR with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.20
  • Number of Estimates 3
  • High Estimate -0.19
  • Low Estimate -0.22
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +4.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.26 +54.42%
on 01/04/23
3.69 -5.42%
on 01/31/23
+1.17 (+50.43%)
since 01/03/23
3-Month
1.88 +85.86%
on 12/12/22
4.88 -28.49%
on 11/09/22
+0.39 (+12.58%)
since 11/03/22
52-Week
1.39 +150.89%
on 09/16/22
4.88 -28.49%
on 11/09/22
+0.83 (+31.20%)
since 02/03/22

Most Recent Stories

More News
Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data

Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tissue sarcoma.

AVEO : 15.00 (unch)
ETON : 3.50 (+0.86%)
MNPR : 3.40 (+0.89%)
IMCR : 63.53 (+0.02%)
Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Monopar Therapeutics Inc. (MNPR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions...

MNPR : 3.40 (+0.89%)
Monopar Therapeutics Inc. (MNPR) Could Find Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics Inc. (MNPR), indicating that the stock has found support. This, combined with an upward trend in earnings...

MNPR : 3.40 (+0.89%)
Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments

Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe and Enrolling Patients Toward Interim Analysis Anticipated in Q1 2023...

MNPR : 3.40 (+0.89%)
Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments

Validive® Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward InterimCamsirubicin Phase 1b Dose-Escalation Trial Clears 3rd Dose Level, Now...

MNPR : 3.40 (+0.89%)
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments

Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe Camsirubicin Phase 1b Dose-Esclation Trial Clears 2nd Dose Level and...

MNPR : 3.40 (+0.89%)
Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference

WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on...

MNPR : 3.40 (+0.89%)
Monopar Announces Clinical and Preclinical Program Updates

Validive Phase 2b/3 VOICE trial now open at 43 sites; active and enrolling in US and EU Open-label Phase 1b camsirubicin trial: early signs of clinical...

MNPR : 3.40 (+0.89%)
Monopar to Present at the H.C. Wainwright BioConnect Conference

WILMETTE, Ill., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on...

MNPR : 3.40 (+0.89%)
Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial

WILMETTE, Ill., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on...

MNPR : 3.40 (+0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Monopar Therapeutics Inc. is a biopharmaceutical company. It is focused on developing drugs for cancer patients. The company's intellectual property pipeline consists of Validive(R), Camsirubicin (MNPR-201) and MNPR-101 which are in clinical stage. Monopar Therapeutics Inc. is based in Wilmette, United...

See More

Key Turning Points

3rd Resistance Point 3.51
2nd Resistance Point 3.44
1st Resistance Point 3.41
Last Price 3.40
1st Support Level 3.31
2nd Support Level 3.24
3rd Support Level 3.21

See More

52-Week High 4.88
Fibonacci 61.8% 3.55
Last Price 3.40
Fibonacci 50% 3.14
Fibonacci 38.2% 2.72
52-Week Low 1.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar